Jurassic Park Isn’t Just a Movie, Startups Hatch Chicks
A de-extinction startup says it hatched 26 live chicks in a lab using a synthetic eggshell, spotlighting frontier bio...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
88 articlesIridex (IRIX) 2026 Earnings: Q1 Review & Outlook Guide
A clear, investor-friendly look at Iridex's Q1 2026 performance and what it could mean for the full year. Learn the n...
What This Fund’s Million Exit Signals Fresh Investor Cues
A major fund’s exit from Ocular Therapeutix raises questions about timing, liquidity, and sector signals. This articl...
Dyne Therapeutics 40% Rally Faces Fund Selloff Questions
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
This Beaten-Down Growth Stock Could Jump 30%, According to Wall Street
A high-flying biotech spin-off has faced a brutal disconnect between hype and reality. This beaten-down growth stock ...
Why This Fund Just Made a $55 Million Bet on Dianthus
A prominent fund has poured roughly $55 million into Dianthus as the stock climbs 350%. This article breaks down what...
Alumis Stock Soared 400%: Cormorant Buys Another $8M
A sharp rise in Alumis shares coincides with a fresh stake from Cormorant Asset Management. This article breaks down ...
China Tech Fund Opens a Biotech Position — What It Signals
A china tech fund opens a biotech position, signaling a broader shift toward life sciences within tech-driven portfol...
Bicara Stock 50% Jump: A Biotech Bet Hits 29%
A sharp move in bicara stock 50% has spotlighted a bold biotech bet that now accounts for nearly a third of one inves...
Nexgel (NXGL) 2026 Earnings Outlook for Investors Today
Nexgel's Q1 2026 earnings reveal the early trajectory of the year. This analysis breaks down the numbers, explains th...
What Know About This Fund’s Exit From Ascendis Pharma
A notable fund liquidated its entire Ascendis Pharma stake, signaling a strategic rotation in a volatile biotech sect...
Fennec (FENC) 2026 Earnings: Q1 Outlook and Takeaways
Investors eye the Fennec Q1 2026 call to gauge milestones, cash runway, and potential catalysts. This guide breaks do...